KPTI

XPOVIO (Selinexor)

Multiple myeloma (Penta-Refractory)

Approved Quarterly Sales

Exp Date

Q2 2020

Amp Volatility Score

27%

Catalyst Info & Data Links

Catalyst Events:

  • Approved Quarterly Sales

  • Commercial sales - 4th line (See image)

  • On its Q1 2020 investor call, KPTI reported slightly decreased revenue for XPOVIO. Management noted challenges with new patient starts in March given Covid pandemic, and suggested that April saw some renewed prescription growth. The March numbers were disappointing because KPTI began the month with positive Boston results in earlier multiple myeloma patients, which might have fueled further growth of XPOVIO even before FDA approval in less heavily pre-treated patients.

 

Prior Data Links:


HC updated 5/22/20

Prior Data (click to view full image)

Chart

Trial Design / Revenue (click to view full image)

Chart

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon